This video features answers from key experts to commonly asked questions regarding optimal treatment sequence and safety profile of chemotherapy regimens used in metastatic pancreatic cancer. Furthermore, second-line treatment options for progressive metastatic pancreatic cancer will be discussed.
Nov 22, 2017
Nov 22, 2018
Gerald Prager, MDMedical University of Vienna
Thomas Seufferlein, MD, PhD University of Ulm
This educational activity is designed for medical oncologists, gastroenterologists, and other healthcare providers involved in the management of patients with pancreatic cancer.
After successful completion of this educational activity, participants should be able to:
- Select an optimal treatment sequence for metastatic pancreatic cancer
- Compare and contrast second-line treatment options for progressive metastatic pancreatic cancer
- Explain adverse events associated with chemotherapy regimens used in metastatic pancreatic cancer and identify management strategies
This educational activity is supported by a grant from Shire.
Independent Medical Education (IME)
This IME activity is organized by prIME Oncology. This activity provides content that is evidence-based, balanced, and free of commercial bias, with a primary objective to improve competence and performance of learners in order to improve patient care.
This activity is provided by prIME Oncology.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.